natgillin/translations-raw huggingface dataset:
3 tablets of INCIVO twice daily (morning and evening) with food.
3 tablete zdravila INCIVO dvakrat na dan (zjutraj in zvečer) s hrano.
3 The frequency of pneumonitis is calculated based on pooled data in 1310 patients in clinical trials receiving Abraxane monotherapy for breast cancer and for other indications using MedDRA SMQ Interstitial lung disease.
3 Pogostnost pnevmonitisa je izračunana na osnovi združenih podatkov pri 1.310 bolnikih v kliničnih preskušanjih, ki so prejemali monoterapijo z zdravilom Abraxane pri raku dojk in drugih indikacijah z uporabo SMQ MedDRA ‘intersticijska bolezen pljuč’.
3 There was no statistically significant difference compared to placebo.
3ni bilo statistično značilne razlike v primerjavi s placebom.
3 This adverse reaction was identified through post-marketing surveillance but not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies for emtricitabine or in randomised controlled clinical studies or the tenofovir disoproxil fumarate expanded access program for tenofovir disoproxil fumarate.
3 Ta neželeni učinek je bil opredeljen v okviru nadzora v obdobju trženja zdravila, vendar ga v randomiziranih kontroliranih kliničnih študijah pri odraslih ali v kliničnih študijah emtricitabina pri otrocih s HIV ali v randomiziranih kontroliranih kliničnih študijah dizoproksiltenofovirijevega fumarata ali v podaljšanem programu dostopanja do dizoproksiltenofovirijevega fumarata niso opazili.
3 This adverse reaction was identified through post-marketing surveillance for emtricitabine but was not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies of emtricitabine.
3 Ta neželeni učinek je bil opredeljen v okviru nadzora za emtricitabin v obdobju trženja zdravila, vendar ga v randomiziranih kontroliranih kliničnih študijah pri odraslih ali v kliničnih študijah emtricitabina pri otrocih s HIV niso opazili.
3 times daily + etravirine
trikrat na dan + 200 mg
3 times-per-week and 40,000 IU, once-weekly regimens in the anaemic cancer subjects were 45.8 and
3-krat na teden in 40.000 i.e. enkrat na teden pri anemičnih osebah z rakom je bil 45,8 oz.
3 to 12 years (N=35)
Od 3 do 12 let
3 to 12 years (N=36)
Od 3 do 12 let
3 to 23 months
3 do 23 mesecev
3 to 36 months
3 až 36 mesiacov
3 to 36 months (N=17)
Od 3 do 36
3 to 36 months (N=18)
Od 3 do 36
3 to 4 % of patients may experience reactions at the injection site (such as reddening, unusually intense pain on injection, itching, hives, swelling or inflammation).
Pri 3 do 4 % bolnikov se lahko pojavijo reakcije na mestu injiciranja (kot so pordelost, nenavadno močna bolečina pri injiciranju, srbenje, koprivnica, otekanje ali vnetje).
3 to 7.5 kg*
3 do 7,5 kg
3 to 8 years
od 3 do 8 let
3 to 8 years
od 3 do 8 let N=51 N=31
3 to 8 years N = 51 N = 47
od 3 do 8 let N=51 N=47
3 to <18 years
3 do < 18 let
3 To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process
3 Če je znano, ali obstaja sum, da so v infekcijsko dogajanje vpleteni grampozitivni patogeni, je treba to zdravilo uporabiti v kombinaciji s protibakterijskim zdravilom, ki deluje proti takšnim patogenom.
3 to less than 20 kg
3 do manj kot 20 kg
3 to less than 4
3 do manj kot 4
3 transdermal patches
3 transdermalni obliži
3 vial adapters with a pre-attached needle
3 adapterje za viale z iglami,
3 Vial adapters with needles + 6 alcohol wipes
3 adapterji za viale z iglami + 6 alkoholnih blazinic
3 vials (10 g/100 ml or 20 g/200 ml).
3 viale (10 g/100 ml ali 20 g/200 ml).
3 vials + 3 ampoules
3 viale
3 vials + 3 ampoules
3 viale + 3 ampule
3 vials + 3 vials
3 viale + 3 viale
3 vials of 5 ml each
3 viale (5 ml)
3 vials of powder.
3 viale s praškom.
3 vials of solvent.
3 viale z vehiklom.
3 vials with powder: 300 microgram (9.6 m IU) per vial.
3 viale s praškom: 300 mikrogramov (9,6 milijonov i.e.) na vialo.
3 Vulvovaginitis, balanitis and related genital infection include the following preferred terms: vulvovaginal mycotic infection, balanoposthitis, genital infection fungal, vaginal infection, and vulvovaginitis.
3 Vulvovaginitis, balanitis in sorodne okužbe spolovil obsegajo naslednje prednostne izraze: vulvovaginalna glivična okužba, balanopostitis, glivična okužba spolovil, okužba nožnice in vulvovaginitis.
3 weeks
3 tedne
3 weeks after completion of the primary course for CPiV and
3 tedne po zaključku osnovnega cepljenja proti CpiV in
3 weeks after completion of the primary course for CPiV.
3 tedne po zaključku osnovnega cepljenja proti CpiV.
3 weeks after initial treatment
3 tedne po začetnem zdravljenju
3 weeks after the first vaccination for CDV, CAV, CPV,
3 tedne po prvem cepljenju proti CDV, CAV, CPV,
3 weeks after the first vaccination for CDV, CAV, CPV, and
3 tedne po prvem cepljenju proti CDV, CAV, CPV, in
3 weeks after the first vaccination for CDV, CAV, CPV.
3 tedne po prvem cepljenju proti CDV, CAV, CPV,
3 weeks n=181
3 tedne n = 181
3 weeks n=277
3 tedne n = 277
3 weeks n=278
n = 278
3 weeks of age or older: 0.5 ml intramuscularly in the breast muscle.
Starost tri tedne ali več: 0,5 ml intramuskularno v prsno mišico.
3 weeks.
LVEF v 3 tednih.
3 When clinical information on the patients was available to make a judgement, approximately
3 Kjer so bile na voljo klinične informacije o bolnikih, je bilo moč ugotoviti, da se je približno
3 Whole body region of interest
3 Opazovano področje je celo telo.
3 x (1 vial + 1 pre-
3 x (1 viala + 1 napolnjena
3 x (30 capsules +
3 x (30 kapsul +
3 x 1 dose (0.5 ml)
3 x 1 odmerek (0,5 ml)
3 x 1 vial +
3 x 1 viala +
3 x 100 mg twice daily
3 x 100 mg dvakrat na dan
3 x 25 mg twice daily
3 x 25 mg dvakrat na dan
3 x 28 tablets (24 active + 4 placebo)
3 x 28 tablet (24 z zdravilnima učinkovinama + 4 placebo)
3 x 30 dose inhaler
3 x 30 odmerkov v inhalatorju
3 x 30 doses
3 x 30 odmerkov
3 x 30 doses
3 × 30 odmerkov
3 x 30 film-coated tablets
3 x 30 filmsko obloženih tablet
3 x 30 hard capsules: EU/1/03/267/010
3 x 30 trdih kapsul: EU/1/03/267/010
3 x 30 tablets
3 x 30 tablet
3 x 60 hard capsules: EU/1/03/267/011
3 x 60 trdih kapsul: EU/1/03/267/011
3 x/week dosing
3 x/teden
3 year CSR Q1 2019
četrtletje 2019
3 years
leta
3 years -
3 leta
3 years After suspension
3 leta Po suspendiranju
3 years at 2 °C – 8 °C.
3 leta pri temperaturi 2 °C – 8 °C
3 years of continuous Zavesca treatment, mean reductions in liver and spleen organ volume were 17.5% and 29.6%, respectively.
Po treh letih stalnega jemanja zdravila Zavesca je bilo povprečno zmanjšanje volumna jeter 17,5 % in vranice 29,6 %.
3 years when stored in a freezer ( -20˚C ±5°C).
3 leta pri shranjevanju v zamrzovalniku (-20 °C ± 5 °C).
3 years, as packaged for sale.
3 leta v originalni ovojnini.
3 years.
leta
3 years.
leta.
3 – 4 days or more until pain and acute
ali več, dokler ne izgine bolečina in preneha
3 – 4 days or more until pain and acute
vsakih 24 ur 3 do 4 dni ali več, dokler
3 – 8 years
3 – 8 let
3 – 8 years
3–8 let
3 “Sphincter of O ddi spasm” t erm i ncludes: m anifestation as p ancreatitis (terms i nclude a lcoholic pancreatitis, pancreatitis, and pancreatitis acute) and hepatic enzyme elevations with abdominal pain (terms include abdominal pain, abdominal pain upper, dyspepsia, and sphincter of Oddi dysfunction).
3 Izraz »spazem Oddijevega sfinktra« vključuje: pojav pankreatitisa (izrazi vključujejo alkoholni pankreatitis, pankreatitis in akutni pankreatitis) in zvišane ravni jetrnih encimov z bolečinami v trebuhu (izrazi vključujejo bolečine v trebuhu, bolečine v zgornjem delu trebuha, dispepsijo in nepravilno delovanje Oddijevega sfinktra).
3% aluminium hydroxide gel expressed as mg Al3+: 1 mg
3 % gel aluminijevega hidroksida, izražen kot mg Al: 1 mg
3% bodyweight loss per month = 0.7% per week = 0.1% per day
3 % izgube telesne mase na mesec = 0,7 % na teden = 0,1 % na dan
3% of patients (18/681) developed persistent antibodies to the PEG moiety of peginterferon beta-1a.
Pri 3 % bolnikov (18/681) so se razvila obstojna protitelesa proti delu PEG v peginterferonu beta-1a.
3% of patients experienced an increase of 60 ms or greater at some point during the trial and 1 patient exhibited a QTcF
3 % bolnikov je imelo zvišanje za 60 ms ali več v določenem času študije in 1 bolnik je imel interval QTcF
3).
Slika 3
3+1 schedule
Shema 3+1
3, 4 months
3. in 4. mesec
3, 4, 5 months schedule
Shema 3., 4., 5. mesec
3, 5 months
3. in 5. mesec
3, 5 months), a booster dose must be given between 11 and 13 months of age; after a primary vaccination with 3 doses of Hexavac (e.g.
3. in 5. mesec) obnovitveno cepljenje izvesti med 11. in 13. mesecem življenja; po primarnem cepljenju s 3 odmerki HEXAVAC-a (npr.
3, 6 or 12 months N=1,718
enoksaparin/AVKb) 3, 6 ali 12 mesecev
3, 6 or 12 months N=1,731
zdravilo Xareltoa) 3, 6 ali 12 mesecev
3, 6 or 12 months N=2,419
zdravilo Xareltoa) 3, 6 ali 12 mesecev
3, 6 or 12 months N=4,131
Enoksaparin/AVKb) 3, 6 ali 12 mesecev
3, 6 or 12 months N=4,150
3, 6 ali 12 mesecev
3, 89079 Ulm Germany
3, 89079 Ulm Nemčija
3,000 IU
3.000 i.e
3,000 IU/0.3 ml
3.000 i.e./0,3 ml
3,000 mg/day
3.000 mg/dan
3,200 units*
1.600 enot*,
3,200 units*,
3.200 enot*,
3,4,5 months
3, 4, 5 mesecev
3,527 (2,231 – 4,526) U/l
3.527 (2.231-4.526) E/l
3,595 patients undergoing major orthopaedic surgery of the lower limbs treated up to 9 days
3.595 bolnikih po veliki ortopedski operaciji na spodnjih okončinah, ki so se zdravili do 9 dni.
3,600 mg/kg/day.
3600 mg/kg/dan.
3-11 years
3-11 let
3-4 mg/kg bodyweight/day
3 - 4 mg/kg telesne mase/dan
3-4) or considered
3-4) ali medicinsko
3-4-5 months N= 1055 (6 studies)
3-4-5 mesecev N = 1055 (6 študij)
3-4.5-6 months N=554
3-4,5-6 mesecev n =554
3-5 years
Od 3 do 5 let
3-5-11 months of age
3-5-11 mesecev starosti
3-6 months
3–6 mesecev
3-6 months)
3-6 mesecev)
3-6, 6-9 and 9-12 month study intervals, respectively.
34,3) in 14 % (IZ: -31,6, 44,2) tekom 0-1, 1-3, 3-6, 6-9 oziroma 9-12 mesečnimi intervali študije.
3-6, 6-9 and 9-12 month study intervals, respectively.
6 % (IZ: -33,5, 34,3) in 14 % (IZ: -31,6, 44,2) tekom 0-1, 1-3, 3-6, 6-9 oziroma 9-12 mesečnimi intervali študije.
3-day regimen of aprepitant in adults
3-dnevni režim zdravljenja z aprepitantom pri odraslih
3-day treatment pack containing: 1 x 125 mg hard capsule and
Pakiranje za 3-dnevno zdravljenje vsebuje: 1 x 125 mg trda kapsula
3-dose
3 odmerki
3-dose primary schedule
Primarno zaporedje cepljenja s 3 odmerki
3-fold the human exposure following administration of the recommended therapeutic dose (based on AUC).
Izpostavljenost je ustrezala do 3-kratni izpostavljenosti človeka po prejetju priporočenega terapevtskega odmerka (na osnovi AUC).
3-Minute stair climb test (stairs/minute)
Triminutni test hoje po stopnicah (stopnic/minuto)
3-month multipack containing 42 (3x14) vials with powder and 42 (3x14) pre-filled syringes with solvent
3-mesečno skupno pakiranje, ki vsebuje 42 (3x14) vial s praškom in 42 (3x14) napolnjenih injekcijskih brizg z vehiklom
3-month multipack containing 42 (3x14) vials with powder and 45 (3x15) pre-filled syringes with solvent
3-mesečno skupno pakiranje, ki vsebuje 42 (3x14) vial s praškom in 45 (3x15) napolnjenih injekcijskih brizg z vehiklom
3-month multipack containing 45 (3x15) vials with powder and 45 (3x15) pre-filled syringes with solvent
3-mesečno skupno pakiranje, ki vsebuje 45 (3x15) vial s praškom in 45 (3x15) napolnjenih injekcijskih brizg z vehiklom
3-month multipack: 42 (3 packs of 14) vials with powder and 45 (3 packs of 15) pre-filled syringes with 1.2 ml solvent.
3-mesečno skupno pakiranje: 42 (3 pakiranja po 14) vial s praškom in 45 (3 pakiranja po 15) napolnjenih injekcijskih brizg z 1,2 ml vehikla
3-month multipack: 45 (3 packs of 15) vials with powder and 45 (3 packs of 15) pre-filled syringes with 1.2 ml solvent.
3-mesečno skupno pakiranje: 45 (3 pakiranja po 15) vial s praškom in 45 (3 pakiranja po 15) napolnjenih injekcijskih brizg z 1,2 ml vehikla
3-month pack comprising 42 (3x14) single packs, each containing:
3-mesečno pakiranje vsebuje 42 (3 x 14) posameznih pakiranj; vsako vsebuje:
3-month pack comprising 45 (3x15) single packs, each containing:
3-mesečno pakiranje vsebuje 45 (3 x 15) posameznih pakiranj; vsako vsebuje:
3-month pack with 3x14 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or
3-mesečno pakiranje s 3 x 14 posameznimi pakiranji; vsako posamezno pakiranje vsebuje 1 vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali
3-month pack with 3x15 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or
3-mesečno pakiranje s 3 x 15 posameznimi pakiranji; vsako posamezno pakiranje vsebuje 1 vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali
3-month packs comprising 3x14 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or titration pack for the first 12 injections comprising 4 triple packs, each containing 3 vials with powder, 3 pre-filled syringes with solvent, 3 vial adapters with needle, 6 alcohol wipes
3-mesečno pakiranje s 3 x 14 posameznimi pakiranji; vsako posamezno pakiranje vsebuje 1 vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali set za titriranje (za prvih 12 injekcij), ki vsebuje štiri tridelna pakiranja; vsako tridelno pakiranje vsebuje 3 viale s praškom, 3 napolnjene injekcijske brizge z vehiklom, 3 adapterje za viale z iglami, 6 alkoholnih blazinic.
3-month packs comprising 3x15 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or
3-mesečno pakiranje s 3 x 15 posameznimi pakiranji; vsako posamezno pakiranje vsebuje 1 vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali
3-O-desacyl-4’- monophosphoryl lipid A (MPL) 2 50 micrograms
3-O-desacil-4'- monofosforil lipid A (MPL) 2 50 mikrogramov
3-O-desacyl-4’- monophosphoryl lipid A (MPL)2 50 micrograms
3-O-desacil-4’- monofosforil lipid A (MPL)2 50 mikrogramov
3-O-desacyl-4’- monophosphoryl lipid A (MPL)3 50 micrograms
3-O-desacil-4’- monofosforil lipid A (MPL)3 50 mikrogramov
3-Year EFS Rate, % (95% CI)
3-letni delež EFS, % (95-odstotni IZ)
3-Year PFS rateb (%) [95% CI] 23 [18, 28] 15 [10, 20]
Delež 3-letnega PFSb (%) [95 % IZ] 23 [18; 28] 15 [10; 20]
3-yearly submission cycle
3-letni cikel predložitve
3.
DFSP
3.) Place ITLC strip in the developing chamber and allow the solvent front to migrate past the 5.4 cm mark.
Vstavite ploščico za ITLC v razvijalno komoro in pustite, da fronta topila potuje prek oznake 5,4 cm.
3.0 m vs 2.6 m
3,0 m v prim. z 2,6 m
3.0 mL (6 million IU/mL)
(6 milijonov
3.0 ml (6 million IU/ml)
3,0 ml (6 milijonov
3.0 ml/h/kg (range 1.6-4.6 ml/h/kg).
3,0 ml/h/kg (območje 1,6 - 4,6 ml/h/kg).
3.0 ng/mL (5.0 to 13 ng/mL) and 2.1  0.70 mg (1.5 to 2.7 mg), respectively (see section 4.2).
± 0,70 mg (od 1,5 do 2,7 mg) (glejte poglavje 4.2).
3.0 point worsening
poslabšanje za 3,0 točke
3.0% (95% CI =
3,0 % (95-odstotni
3.03 log10 copies/ml; +263 and +283 cells/mm3 in the tenofovir disoproxil 245 mg (as fumarate) and stavudine groups, respectively).
+263 celic/mm3 v skupini z 245 mg dizoproksiltenofoviratom (v obliki dizoproksiltenofovirijevega fumarata) ter -3,03 log10 kopij/ml in +283 celic/mm3 v stavudinski skupini).
3.1 (2.8, NR)
3,1 (2,8, ND)
3.1-4.0 mmol/l (56-72 mg/dl)
< 3,1 mmol/l (< 56 mg/dl)
3.2 ml solvent in a vial, 1 vial adapter
3,2 ml vehikla v viali nastavek za vialo za pripravo zdravila
3.2 ml water for injections
3,2 ml vode za injekcije
3.2 to 3.4 mmHg for the brinzolamide group and 3.2 to 4.2 mmHg for the timolol group were observed.
4,2 mmHg za skupino, ki je prejemala timolol.
3.26B [2.45; 4.33]
2,38B [1,78; 3,18]
3.3 ml once daily
3,3 ml enkrat na dan
3.3 ml twice daily
3,3 ml dvakrat na dan
3.4%
placebo
3.4%
Vrednost p
3.4% (-6.0% to 12.9%)
3,4 % (–6,0 % do 12,9 %)
3.5 - 7 mg/kg/day
3,5 - 7 mg/kg pri bolnikih, ki prejemajo odmerke
3.5 hours, with a clearance rate of approximately 0.6 ml/min/kg.
Razpolovni eliminacijski čas odstranjevanja filgrastima iz telesa znaša približno 3,5 ur; očistek znaša približno 0,6 ml/min/kg.
3.5 hours.
2,0 ure povečala na 3,5 ure.
3.5 log 10 CCID50 per dose
CCID50 na odmerek
3.5 mg / 2.5 ml 1 vial + 1 vial
3,5 mg/2,5 ml 1 viala + 1 viala
3.5 mg / 2.5 ml 2 vials + 2 vials
3,5 mg/2,5 ml 2 viale + 2 viale
3.5 mg/vial
3,5 mg
3.5 mg/vial 1 vial
1 viala
3.5 ml twice daily
3,5 ml dvakrat na dan
3.5 mmol/l), potassium levels should be corrected prior to use of BRINAVESS.
3,5 mmol/l) je treba pred uporabo zdravila BRINAVESS korigirati koncentracijo kalija.
3.5 to 10.5 mg /kg (0.035 to 0.105 ml/kg) twice daily
3,5 do 10,5 mg/kg (0,035 do 0,105 ml/kg) dvakrat na dan
3.5 to 7 mg/kg (0.035 to
3,5 do 7 mg/kg (0,035 do
3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily
0,14 ml/kg) enkrat na dan (2) (4)
3.5-4.4 g/dl)
zmanjšanje 35-44 g/l)
3.52 (41.7%)
0,68AC [0,53; 0,87]
3.541
(n=287)
3.541
(n=87)
3.6 to 5.0 log10 PFU Excipient......................................................................................................................................qs 1 dose
3,6 log10 PFU Pomožna snov ..................................................................................................................... q.s 1 odmerek
3.6% (2.6-5.0 x ULN)
3,6% (2,6-5,0 x ULN)
3.6% (95% CI =
3,6 % (95-odstotni
3.7 m vs 5.9 m
3,7 m v prim. s
3.7% (2 subjects)
3,7% (2 bolnika)
3.7% (95% CI: 0.4% to 7.0%. p < 0.017c)
3,7 % (95 % IZ: 0,4 % do 7,0 %. p < 0,017c)
3.75 micrograms haemagglutinin/dose
3,75 mikrogramom hemaglutinina/odmerek
3.78 to 5.16
3,78 to 5,16
3.8 (NR, NR)
3,8 (ND, ND)
3.8 ml for 3.0 mg dose
3,8 ml za odmerek 3,0 mg.
3.8 ml once daily
3,8 ml enkrat na dan
3.8 ml twice daily
3,8 ml dvakrat na dan
3.8  2.8. Of these, 72 (89%) had Laron syndrome-like phenotype; 7 (9%) had GH gene deletion, 1 (1%) had neutralizing antibodies to GH and 1 (1%) had isolated genetic GH deficiency.
Od teh je 72 oseb (89 %) imelo fenotip, podoben Laronovemu sindromu, 7 oseb (9 %) delecijo gena za GH, 1 oseba (1 %) nevtralizirajoča protitelesa proti GH in 1 oseba (1 %) izolirano genetsko pomanjkanje GH.
3.9 (3.02 to 4.30)
ZALTRAP/FOLFIRI (n = 552)
3.9 mg pyriproxifen, 317 mg permethrin
3.9 mg piriproksifen, 317 mg permetrin
3.94 points (SD: 1.95; 95%; CI: 2.97–4.91)
3,94 točke (SD: 1,95, 95 %, CI: 2,97–4,91)
3.98B [3.05; 5.18]
2,82B [2,17; 3,67]
3/ INSERT NEEDLE RAPIDLY PERPENDICULAR TO THE SKIN
3/ IGLO HITRO PRAVOKOTNO VSTAVITE SKOZI KOŽO
3/3 of these patients had cirrhosis.
3 od teh 3 bolnikov so imeli cirozo.
30 ampoules
30 ampul
30 AMPOULES WITH 2 ML
30 AMPUL Z 2 ML
30 April 2010
30. april 2010
30 capsules
30 trdih kapsul
30 chewable tablets
30 žvečljivih tablet
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Pošljite vprašanje prek naše spletne strani. www.ema.europa.eu/contact
30 coated tablets
30 obloženih tablet
30 day (for HDPE 30’s count)
30 dni (za HDPE vsebnike s 30 tabletami)
30 day (for HDPE 30’s count)
30 dni (za plastenke iz polietilena visoke gostote po 30 kapsul)
30 day Composite
30 dnevna kompozita
30 days without being refrigerated again during this period and must be discarded if not used during these 30 days.
+25 °C do 30 dni, brez ponovnega shranjevanja v hladilniku v tem času, in ga morate zavreči, če ga ne uporabite v teh 30 dneh.
30 dispersible tablets
30 disperzibilnih tablet
30 doses
14odmerkov 30 odmerkov
30 doses ELLIPTA
30 odmerkov ELLIPTA
30 dosing syringes
30 odmernih brizg
30 film-coated tablets
30 filmsko obloženih tablet.
30 film-coated tablets
30 filmsko obloženimi
30 film-coated tablets
30 x 1 filmsko obložena tableta
30 Film-coated tablets 30x1 Film-coated tablets
30 filmsko obloženih tablet 30 x 1 filmsko obložena tableta
30 film-coated tablets 50 film-coated tablets 100 film-coated tablets
30 filmsko obloženih tablet 50 filmsko obloženih tablet 100 filmsko obloženih tablet
30 film-coated tablets 60 film-coated tablets 120 film-coated tablets
30 filmsko obloženih tablet 60 filmsko obloženih tablet 120 filmsko obloženih tablet
30 film-coated tablets: bottle
30 filmsko obloženih tablet: plastenka
30 film-coated tablets: EU/1/12/763/001 60 film-coated tablets: EU/1/12/763/002 120 Film-coated tablets: EU/1/12/763/003
30 filmsko obloženih tablet: EU/1/12/763/001 60 filmsko obloženih tablet: EU/1/12/763/002 120 filmsko obloženih tablet: EU/1/12/763/003
30 film-coated tablets: EU/1/12/763/007 60 film-coated tablets: EU/1/12/763/008 120 film-coated tablets: EU/1/12/763/009
30 filmsko obloženih tablet: EU/1/12/763/007 60 filmsko obloženih tablet: EU/1/12/763/008 120 filmsko obloženih tablet: EU/1/12/763/009
30 film-coated tablets: EU/1/12/763/013 60 film-coated tablets: EU/1/12/763/014 120 film-coated tablets: EU/1/12/763/015
30 filmsko obloženih tablet: EU/1/12/763/013 60 filmsko obloženih tablet: EU/1/12/763/014 120 filmsko obloženih tablet: EU/1/12/763/015
30 hard capsules.
30 trdih kapsul.
30 hard capsules: EU/1/03/267/008
30 trdih kapsul: EU/1/03/267/008
30 hard capsules: EU/1/03/267/009
30 trdih kapsul: EU/1/03/267/009
30 hard gastro-resistant capsules 100 hard gastro-resistant capsules 250 hard gastro-resistant capsules 500 hard gastro-resistant capsules
30 trdih gastrorezstentnih kapsul 100 trdih gastrorezistentnih kapsul 250 trdih gastrorezistentnih kapsul 500 trdih gastrorezistentnih kapsul
30 IU/kg (21;
30 a.e./kg
30 June 2017
30. junij 2017
30 kg and above
30 kg in več
30 mg (suspension or capsules) once weekly
30 mg (suspenzija ali kapsula) enkrat na teden
30 mg (suspension or capsules) single dose
30 mg (suspenzija ali kapsula) v enkratnem odmerku
30 mg after each haemodialysis session
30 mg po vsaki hemodializi
30 mg after every second haemodialysis session
30 mg po vsaki drugi hemodializi
30 mg BID APR*
30 mg dvakrat na dan APR
30 mg emodepside, 150 mg praziquantel.
emodepsid 30 mg, prazikvantel 150 mg
30 mg hard gastro-resistant capsules
30 mg trde gastrorezistentne kapsule
30 mg of ibafloxacin per ml of gel
30 mg ibafloksacina v 1 ml gela
30 mg once daily single dose3
enkraten odmerek 30 mg enkrat na dan3
30 mg once weekly
30 mg enkrat na teden
30 mg oseltamivir suspension delivers 0.9 g of sorbitol.
30 mg suspenzije oseltamivir vsebuje 0,9 g sorbitola.
30 mg QD
30 mg enkrat na
30 mg single dose
30 mg v enkratnem odmerku
30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg once daily.
Enkraten 30-mg intravenski bolus in subkutani odmerek 1 mg/kg, čemur sledi 1 mg/kg enkrat na dan.
30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg once daily.
Enkraten 30-mg intravenski bolus in subkutani odmerek 1 mg/kg, čemur sledi subkutani odmerek 1 mg/kg enkrat na dan.
30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg once daily.
Enkraten 30-mg intravenski bolus sočasno s subkutanim odmerkom 1 mg/kg TM, ki mu sledi 1 mg/kg TM enkrat na dan.
30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg twice daily.
Enkraten 30-mg intravenski bolus in subkutani odmerek 1 mg/kg, čemur sledi subkutani odmerek 1 mg/kg dvakrat na dan.
30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg twice daily. (Maximum 100 mg for each of the first two subcutaneous doses)
Enkraten 30-mg intravenski bolus sočasno s subkutanim odmerkom 1 mg/kg TM, ki mu sledi subkutani odmerek 1 mg/kg TM dvakrat na dan. (Največ 100 mg za vsakega od prvih dveh subkutanih odmerkov.)
30 mg tablet: blue, round (diameter: 8 mm), shallow-convex, debossed with “OTSUKA” and “30” on one side.
90-mg tableta: modra, peterokotna (večja os: 9,7 mm, manjša os: 9,5 mm), plitko konveksna z vtisnjenim napisom "OTSUKA" in "90" na eni strani.